Bucillamine Just Got Cleared for Phase 3 Trials of COVID-19 On Friday, July 31, 2020 Revive Therapeutics (CSE: RVV) (OTC: RVVTF) announced U.S. FDA approval for a confirmatory Phase 3 clinical trial for Bucillamine as a treatment for COVID-19. The Phase 3 study will be titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in … Continue reading Three Things to Know About ‘Phase 3 COVID Player’: Revive Therapeutics